Literature DB >> 15175001

Central core disease mutations R4892W, I4897T and G4898E in the ryanodine receptor isoform 1 reduce the Ca2+ sensitivity and amplitude of Ca2+-dependent Ca2+ release.

Guo Guang Du1, Vijay K Khanna, Xinghua Guo, David H MacLennan.   

Abstract

Three CCD (central core disease) mutants, R4892W (Arg4892-->), I4897T and G4898E, in the pore region of the skeletal-muscle Ca2+-release channel RyR1 (ryanodine receptor 1) were characterized using a newly developed assay that monitored Ca2+ release in the presence of Ca2+ uptake in microsomes isolated from HEK-293 cells (human embryonic kidney 293 cells), co-expressing each of the three mutants together with SERCA1a (sarcoplasmic/endoplasmic-reticulum Ca2+-ATPase 1a). Both Ca2+ sensitivity and peak amplitude of Ca2+ release were either absent from or sharply decreased in homotetrameric mutants. Co-expression of wild-type RyR1 with mutant RyR1 (heterotetrameric mutants) restored Ca2+ sensitivity partially, in the ratio 1:2, or fully, in the ratio 1:1. Peak amplitude was restored only partially in the ratio 1:2 or 1:1. Reduced amplitude was not correlated with maximum Ca2+ loading or the amount of expressed RyR1 protein. High-affinity [3H]ryanodine binding and caffeine-induced Ca2+ release were also absent from the three homotetrameric mutants. These results indicate that decreased Ca2+ sensitivity is one of the serious defects in these three excitation-contraction uncoupling CCD mutations. In CCD skeletal muscles, where a mixture of wild-type and mutant RyR1 is expressed, these defects are expected to decrease Ca2+-induced Ca2+ release, as well as orthograde Ca2+ release, in response to transverse tubular membrane depolarization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175001      PMCID: PMC1133812          DOI: 10.1042/BJ20040580

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  52 in total

Review 1.  Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca(2+) release channels?

Authors:  Robert T Dirksen; Guillermo Avila
Journal:  Trends Cardiovasc Med       Date:  2002-07       Impact factor: 6.677

Review 2.  Malignant hyperthermia and central core disease: disorders of Ca2+ release channels.

Authors:  J Loke; D H MacLennan
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

3.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

Review 4.  Ryanodine receptors of striated muscles: a complex channel capable of multiple interactions.

Authors:  C Franzini-Armstrong; F Protasi
Journal:  Physiol Rev       Date:  1997-07       Impact factor: 37.312

5.  Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.

Authors:  K Censier; A Urwyler; F Zorzato; S Treves
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

6.  Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.

Authors:  J Tong; H Oyamada; N Demaurex; S Grinstein; T V McCarthy; D H MacLennan
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

7.  Molecular identification of the ryanodine receptor Ca2+ sensor.

Authors:  S R Chen; K Ebisawa; X Li; L Zhang
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

8.  Two mechanisms of quantized calcium release in skeletal muscle.

Authors:  M G Klein; H Cheng; L F Santana; Y H Jiang; W J Lederer; M F Schneider
Journal:  Nature       Date:  1996-02-01       Impact factor: 49.962

Review 9.  Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects.

Authors:  J R Mickelson; C F Louis
Journal:  Physiol Rev       Date:  1996-04       Impact factor: 37.312

10.  Alteration of intracellular Ca2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia.

Authors:  S Treves; F Larini; P Menegazzi; T H Steinberg; M Koval; B Vilsen; J P Andersen; F Zorzato
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

View more
  9 in total

1.  Single channel properties of heterotetrameric mutant RyR1 ion channels linked to core myopathies.

Authors:  Le Xu; Ying Wang; Naohiro Yamaguchi; Daniel A Pasek; Gerhard Meissner
Journal:  J Biol Chem       Date:  2008-01-01       Impact factor: 5.157

Review 2.  Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.

Authors:  F Lehmann-Horn; K Jurkat-Rott; R Rüdel
Journal:  Acta Myol       Date:  2008-12

3.  Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).

Authors:  Tram Anh Ta; Isaac N Pessah
Journal:  Neurotoxicology       Date:  2006-08-30       Impact factor: 4.294

4.  Calcitonin gene-related peptide restores disrupted excitation-contraction coupling in myotubes expressing central core disease mutations in RyR1.

Authors:  Ana Victoria Vega; Roberto Ramos-Mondragón; Aida Calderón-Rivera; Angel Zarain-Herzberg; Guillermo Avila
Journal:  J Physiol       Date:  2011-08-08       Impact factor: 5.182

5.  Pore dynamics and conductance of RyR1 transmembrane domain.

Authors:  David Shirvanyants; Srinivas Ramachandran; Yingwu Mei; Le Xu; Gerhard Meissner; Nikolay V Dokholyan
Journal:  Biophys J       Date:  2014-06-03       Impact factor: 4.033

6.  Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease.

Authors:  Natalia Kraeva; Elena Zvaritch; Ann E Rossi; Sanjeewa A Goonasekera; Hilal Zaid; Wanda Frodis; Alexander Kraev; Robert T Dirksen; David H Maclennan; Sheila Riazi
Journal:  Neuromuscul Disord       Date:  2012-11-24       Impact factor: 4.296

Review 7.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

8.  Ca2+ release in muscle fibers expressing R4892W and G4896V type 1 ryanodine receptor disease mutants.

Authors:  Romain Lefebvre; Claude Legrand; Linda Groom; Robert T Dirksen; Vincent Jacquemond
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

Review 9.  Central core disease.

Authors:  Heinz Jungbluth
Journal:  Orphanet J Rare Dis       Date:  2007-05-15       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.